Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Planas Giner, A."'
Autor:
Álamo-Junquera, Dolores, Sala, Núria, Millet, Joan-Pau, Ortega-Gutiérrez, Lluïsa, Planas-Giner, Albert, Rovira, Carol, Comet, Dolors
Publikováno v:
In Atencion Primaria January 2015 47(1):32-37
Autor:
M Cano Alonso, A Planas-Giner, N Almendros-Abad, A Sosa-Pons, L Cardona Roca, L Coronel Cordero, M Roig Soronellas, N Rudi Sola
Publikováno v:
Section 6: Education and research.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6a7ce8e297cb4b7d0b924b0a360a9f9
https://doi.org/10.1136/ejhpharm-2023-eahp.348
https://doi.org/10.1136/ejhpharm-2023-eahp.348
Autor:
Dolores Álamo-Junquera, Núria Sala, Joan-Pau Millet, Lluïsa Ortega-Gutiérrez, Albert Planas-Giner, Carol Rovira, Dolors Comet
Publikováno v:
Atención Primaria, Vol 47, Iss 1, Pp 32-37 (2015)
Objetivo: Conocer la proporción de población potencialmente excluida de cobertura sanitaria a partir del Real Decreto-Ley 16/2012. Describir el uso de servicios sanitarios, la distribución de patología crónica e infecciosa y el gasto farmacéuti
Externí odkaz:
https://doaj.org/article/278ce22767cc4b31980b434dbe8e7fca
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::acae656455170a7afb83577dacdd2990
https://doi.org/10.1136/ejhpharm-2022-eahp.151
https://doi.org/10.1136/ejhpharm-2022-eahp.151
Autor:
MA Perez Quiros, N Almendros-Abad, L Borras-Trias, C Seguí-Solanes, A Planas-Giner, Aldirra-Taha, R Rodriguez-Mauriz, M Cortés-Sansa, N Rudi-Sola
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background Imatinib (IM) is a tirosin kinase inhibitor approved to treat chronic myeloid leukaemia (CML) and other diseases. This drug can be administrated in commercial and generic formulations. Not all generic formulations are exactly designed as t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7926476d13737fc589aca390d758a1e1
https://doi.org/10.1136/ejhpharm-2019-eahpconf.489
https://doi.org/10.1136/ejhpharm-2019-eahpconf.489
Autor:
N Almendros-Abad, L Borràs Trias, R Rodriguez Mauriz, C Seguí Solanes, N Rudi Sola, MA Pérez-Quirós, MA Aldirra-Taha, A Planas-Giner
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background Neutropaenia is one of the most common adverse effects of paclitaxel. It is dose-dependent and has dose-limiting toxicity. However, the American Society of Clinical Oncology (ASCO) guideline recommends the use of real bodyweight for chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::321ee677c1a249665c12c9259c30db2d
https://doi.org/10.1136/ejhpharm-2019-eahpconf.496
https://doi.org/10.1136/ejhpharm-2019-eahpconf.496
Autor:
Aldirra-Taha, N Almendros Abad, C Seguí Solanes, L Borràs Trias, N Rudi Sola, MA Pérez-Quirós, R Rodriguez Mauriz, A Planas-Giner
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background The use of panitumumab in the treatment of metastatic colorectal cancer (mCRC) remains controversial because of its risk/benefit profile. Purpose The aim of this study was to investigate the efficacy and safety of panitumumab in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a1bd242d21e3f5a7b7c619b5c1bf66b
https://doi.org/10.1136/ejhpharm-2019-eahpconf.479
https://doi.org/10.1136/ejhpharm-2019-eahpconf.479
Autor:
Aldirra-Taha, M. S., Sagalés-Torra, M., Planas-Giner, A., Cárdaba-García, M. E., Pérez-Quirós, M. A., Rudi Sola, N.
Publikováno v:
El Farmacéutico Hospitales; ene2020, Issue 217, p23-37, 15p
Publikováno v:
Farmacia Hospitalaria. 32:127-129
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f6ea559f1b5bb5b1a28945162294b2c
https://doi.org/10.1016/s1130-6343(08)72826-5
https://doi.org/10.1016/s1130-6343(08)72826-5
Autor:
Dolores, Álamo-Junquera, Núria, Sala, Joan-Pau, Millet, Lluïsa, Ortega-Gutiérrez, Albert, Planas-Giner, Carol, Rovira, Dolors, Comet
Publikováno v:
Atencion Primaria
Resumen Objetivo Conocer la proporción de población potencialmente excluida de cobertura sanitaria a partir del Real Decreto-Ley 16/2012. Describir el uso de servicios sanitarios, la distribución de patología crónica e infecciosa y el gasto farm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f1416a5d3f6ef736496d1b22c49be0d0
https://pubmed.ncbi.nlm.nih.gov/25241354
https://pubmed.ncbi.nlm.nih.gov/25241354